From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system syndrome, was treated with methyl phenidate, clonidine and fluoxetine [10] . Over a 10-month period, he developed gastrointestinal toxicity, incoordination and disorientation, and seizures. He died from a cardiac arrest. Postmortem toxicology showed high fluoxetine and norfluoxetine concentrations, and PGx revealed a poor CYP2D6 metabolizer genotype, resulting in fluoxetine accumulation and toxicity. Subsequently, the boy's parent were absolved from involvement in fluoxetine intoxication. Another example is genotyping uridine 5´-diphosphate-glucuronyltransferase 1A1 for patients medicated with irinotecan to avoid hematopoietic toxicity [11] ; Drug sensitivity: in addition to warfarin, one should genotype HLA-B*5701 [12] and HLA-B*1502 [13] for patients medicated with abacavir [12] and some antiepileptics [13] , respectively, to avoid Stevens-Johnson syndrome. Lawyers use internet advertising to reach persons who may be affected [103] .
In establishing PJ, a firm foundation should be based on sound legal principles as well as reliable and valid evidence-based studies, not on 'junk' science and unsubstantiated case reports. This lesson resonates in the deficiencies that beset various forensic sciences recently reported by the National Academy of Science [14, 104] . The American Academy of Forensic Sciences supports the National Academy of Science's 13 recommendations and the following principles: the need for strong scientific foundations; laboratory accreditation; certification of technicians; the standardization of terminology; ethical protocols; governmental oversight; and the education of legal professionals, including judges, in forensic scientific methods and principles [15, 16, 105] . It is imperative that PJ heeds these recommendations, including the study of the relationship Enabled by pharmacogenomics (PGx), molecular imaging and other molecular biomarkers, personalized medicine (PM) promises to optimize therapy while minimizing side effects. It may also dramatically impact the justice system in ways we are only beginning to understand.
Personalized medicine has already entered the curricula of well-regarded medical schools such as that of Johns Hopkins University (MD, USA) [ [3, 4, 101] . If PGx retrospectively reveals that the warfarin patient was at high risk and testing was not initially performed, litigation may follow. Indeed, some lawyers advertise on the internet for cases involving warfarin-related errors [102] . Consequently, PGx may become part of defensive medicine.
Personalized justice (PJ) complements PM and the overlapping practice of translational medicine [5] [6] [7] [8] , which holds that individual differences are caused primarily by genetic and environmental factors. The acronym 'TSPB' captures its elements in relation to adverse drug reactions (ADRs): toxicity, sensitivity, impaired performance (e.g., driving under the influence of drugs) and behavioral changes. Future legal applications may include molecular imaging and analyses -genomic, proteomic, metabolomics and epigenetics/imprintomics. By comparison, molecular DNA fingerprinting for identity testing is well accepted [9] . Conceptually, Figure 1 proposes a social-balance relationship for PM and PJ [8] .
In assessing PJ, consider two index scenarios: Drug toxicity: a 9-year old boy, diagnosed with attention-deficit hyperactivity disorder, obsessive-compulsive disorder, and Tourette's The prime questions though will relate to the role PJ will play in the legal system. DNA evidence thus far is narrowly confined to trace evidence: was this biological evidence left by the defendant or someone else? A thornier problem occurs when we attempt to apply biological evidence to moral culpability, which pertains to an accused's personal blameworthiness. The Supreme Court recognized in Penry v. Lynaugh that punishment for a criminal offense should be directly related to the defendant's personal culpability [21] . The concept of personal culpability acknowledges that human choices are shaped by many factors: genetic, neurological, intellectual, educational, social and environmental. It follows then that an individual's blameworthiness for criminal conduct may vary depending on the factors that shaped his moral development or compromised his choices.
"...should courts consider identifiable biological conditions that predispose a person to criminal behavior in weighing moral culpability? Legal precedent suggests that it should."
Thus, from a PJ perspective, the question becomes something like this: should courts consider identifiable biological conditions that predispose a person to criminal behavior in weighing moral culpability? Legal precedent suggests that it should. Consider Roper v. Simmons, where the Supreme Court held that persons under the age of 18 years could not be subjected to the death penalty because their brains were not yet fully developed [22] . MRIs and neuroimaging showed that neuronal changes in the brain continued to develop into the early twenties. Since the brain affects behavior, the justices ruled that punishing a person for behavior caused by an underdeveloped brain (of which the defendant had no choice) violated the prohibition against cruel and un usual punishment. Similar logic was applied in Atkins v. Virginia, which prohibited subjecting the mentally retarded defendants to future science group www.futuremedicine.com
Translational pharmacogenomics in the justice system Editorial the death penalty [23] . Roper and Atkins illustrate the principle that criminal defendants with brain-based deficits are not as morally culpable as those without. As such, they deserve a lesser penalty. This is a legal springboard for PJ.
Forensic pathology perspectives
For several medical examiner/coroner offices in the USA and Europe, PGx has served as an adjunct for drug death certification -an emerging practice of molecular autopsy [7, 8] . Previous studies showed a higher prevalence of CYP2D6 genetic variations, corresponding to intermediate and slow metabolizers with decreased or without enzymatic activity, in the decedents intoxicated with methadone, oxycodone and antidepressants [7, 8, 24, 25] . Thus, PGx might aid in the interpretation of the effect of impaired drug metabolism due to genetic variations. If potentially lethal medications are identified at the scene of a crime with correspondingly toxic drug concentrations of the decedent, and subsequent PGx testing confirms an 'extensive' (normal) metabolizer, death is certified as a suicide. If the deceased's genotype is a variant -resulting in decreased drug metabolism -death is certified as accident. Recent indications of PJ for forensic pathology include a PGx section in the forensic toxicology texts for medical examiners by Molina [26] and Karch [27] . Future molecular diagnostic biomarkers of interest might include epigenetics/imprintomics and gene expression in understanding suicide [28, 29] , metabolomics and proteomics [8] .
"...criminal defendants with brain-based
deficits are not as morally culpable as those without. As such, they deserve a lesser penalty. This is a legal springboard for personalized justice."
Molecular diagnostics
The detection of individual genetic variants is at the heart of PM and PJ. SNPs, the most common type of genetic variation, might affect drug metabolism [30] . 
Drug hypersensitivity in vitro diagnostics
In vitro lymphocyte toxicity assays (LTAs) compares the peripheral blood lymphocytes of patients with a history of an ADR with control individuals who take the same drug in the same dose and do not present any ADR [31] . LTA is based upon the dysfunction of mitochondria in people hypersensitive to certain drugs, such as sulfonamides, NSAIDs, protease inhibitors and antiepileptics. This test can also detect possible drug-drug interactions. Dysfunction of mitochondria has severe cellular consequences and is linked to a lack of detoxification of drugs in humans. Several surveillance strategies have evolved that limit mitochondrial damage and ensure cellular integrity. Intra-organellar proteases conduct protein quality control and exert regulatory functions, allowing the mitochondria to protect against apoptosis. LTA can be used in PJ when several drugs are implicated in an ADR in order to enable a distinction between the drug that produced the reaction and the other drugs, which were taken in the same period of time but did not contribute to the ADR.
Illustrative cases & scenarios
Alcohol Alcoholism, with up to 30-40% inheritability, is a complex and controversial disease future science group Editorial Wong, Happy, Blinka et al.
with both environmental and genetic components. Genetic variations influence alcohol's pharmaco kinetics/metabolism and pharmacodynamics. Alcohol dehydrogenase and acetaldehyde dehydrogenase are two main polymorphic enzymes involved in alcohol metabolism, with a minor contribution from CYP2E1. Pharmacodynamic systems influenced by PGx are: GABA A/B receptors, glutamate (NMDA and a-amino-3-hydroxyl-5-methyl-isoxazolepropionate), serotonin, voltage-activated calcium channels, dopamine/norepinepherine/ acetylcholine and opioid systems. For example, naltrexone, used for detoxification, binds to opioid receptor µ1, and the variants of the candidate gene of this receptor may affect addiction treatment [32, 33] .
Antidepressants & antipsychotics Personalized justice might address the effect of antidepressant and/or antipsychotics on behavioral changes. A recent review examined the relationship of violent behavior to the antidepressants: paroxetine, sertraline and fluoxetine. Different verdicts in a series of medicolegal cases reflected the different judicial processes, without considering drug-induced violence [34] . Incidentally, co-author Lucire studied patients medicated with antidepressants and antipsychotics metabolized by polymorphic CYPs, and assessed the development of akathisic, suicidal and/or homicidal ideations, and their relationship to CYP gene variations [Lucire Y, Pers. Comm.]. The validity of these preliminary observations are pending publication in peer-reviewed journals and validation by other investigators.
Warfarin Oral warfarin anticoagulation is widely used to prevent thromboembolic events. Dosing selection is due to a narrow therapeutic range with a large interindividual variation (20-fold) affected by genetic and nongenetic factors [35, 36] . Approximately 10-17% of patients experience bleeding [35] . Genotyping of CYP2C9, CYP4F2, VKORC1 and relevant clinical factors account for up to approximately 56% of dosing variability [37, 38] . In 2007, the FDA relabeled warfarin to suggest genotyping, followed by the 22 January 2010 relabeling [ Pain management In addressing pain management with safety, Dr Woodcock of the FDA discussed the balance of providing patients with efficacious analgesics and the associated risks [39] . For example, in ultrarapid metabolizers, greater CYP2D6 activity can lead to poisoning after opioid administration. A 2007 case report detailed a breast-feeding infant who suffered respiratory depression and died as a result of toxic amounts of morphine being present in the milk [40] . The mother, later identified with multiple copies of CYP2D6 genes corresponding to an ultrarapid metabolizer, 'overconverted' codeine to a 'high' amount of morphine. This was excreted into breast milk, resulting in the baby's high morphine concentrations, which was identified in postmortem ana lysis. Consequently, guidelines were developed for breast-feeding mothers medicated with codeine.
Conclusion
In recognizing the complementary, check and balance relationship of PM and PJ, translational PGx may serve the promising role of an adjunct biomarker for interpreting drug-related toxicity and sensitivity. Currently, robust, scientific and clinical studies substantiating the relationship between PGx and behavioral and/or performance changes are lacking [34] . These desired PJ studies are challenging to perform because of ethical and legal considerations and a lack of funding. Consequently, interpretations may be extrapolated from case reports, or clinical Box 1. Advantages and disadvantages of using pharmacogenomics as an adjunct biomarker in personalized justice.
Advantages:
DNA is stable in postmortem settings It provides a personalized approach for assessing drug response It can assist in the interpretation of drug concentrations in postmortem toxicology and drug death certification It can assess patient compliance The turnaround time is suitable for medicolegal and/or forensic applications The cost of pharmacogenomics is 'low' in comparison with the legal settlement It might differentiate between chronic versus acute toxicity
Disadvantages:
Data are available in clinical cases but are limited in postmortem cases Legal interpretation is challenging owing to its complexity Drug inhibitors, inducers of enzymes and environmental factors complicate interpretation It does not account for post-translational modifications Multiple enzyme systems are involved in metabolism behavioral and performance studies; for example, studies related to 'driving under the influence of drug'. Other advances include automated platforms and the potential use of oral fluid for toxicology and PGx. Oral fluid, currently being evaluated for forensic drug testing [41] [42] [43] [44] and therapeutic drug monitoring, is easily collected for PM and PJ pending outcome studies to demonstrate efficacy comparable to blood samples. In considering PGx for PJ, advantages and disadvantages are listed in Box 1.
In ushering PJ practice in with PGx, a working group should consist of colleagues from inter-related disciplines in order to probe and keep abreast of recent developments, to grade evidence of case reports and outcome studies, and to develop inclusion and exclusion criteria. With sound scientific and legal principles and correct interpretation, a firm and lasting foundation could support the emerging concept of PJ becoming a reality to enhance patient safety and maintain social justice. No writing assistance was utilized in the production of this manuscript.
